Consensus Novavax, Inc. Mexican S.E.

Stocks

NVAX *

US6700024010

Biotechnology & Medical Research

End-of-day quote Mexican S.E. 2026-09-25			5-day change	1st Jan Change
189.00 ^MXN	+1.23%		+9.89%	+58.15%

09-10	Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10:00 AM
09-09	Novavax, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 09:45 AM

1ae42932.J-MWM5O6JB7GewyBaopPJ-KUT8xJlij5s1g1MPNxJBk.SpN1XvHRbXSLC2qxC8Ypfa3eK_4QyR6J1xBcVJUdUXJEh1tx9NR1RIcoRQ~213cfbda5cb450eb231423a95233cbf8

Analysts' recommendations: Novavax, Inc.

04-09	B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating	MT
11-11	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
11-10	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
25-08-20	Novavax: BofA downgrades stock
25-08-20	Novavax Faces 'Increasingly Murky' Outlook on Vaccine Uncertainties, BofA Securities Says	MT
25-08-20	BofA Downgrades Novavax to Underperform From Neutral, Adjusts Price Target to $7 From $9	MT
25-08-20	BofA Securities Downgrades Novavax to Underperform From Neutral, Price Target is $7	MT
25-05-05	B. Riley Cuts Price Target on Novavax to $18 From $22, Keeps Buy Rating	MT
25-02-28	BTIG Initiates Novavax at Buy With $19 Price Target	MT
24-11-18	B. Riley Adjusts Novavax Price Target to $22 From $26, Maintains Buy Rating	MT
24-10-16	Jefferies Cuts Novavax's Price Target to $25 From $31, Buy Rating Maintained	MT
24-10-10	B. Riley Raises Price Target on Novavax to $26 From $23, Keeps Buy Rating	MT
24-08-12	B. Riley Adjusts Price Target on Novavax to $23 From $25, Maintains Buy Rating	MT
24-08-02	B. Riley Adjusts Price Target on Novavax to $25 From $29, Maintain Buy Rating	MT
24-07-30	Novavax Shares Sink After JPMorgan Downgrades Rating to Underweight From Neutral	MT
24-07-30	JPMorgan Downgrades Novavax to Underweight From Neutral, Adjusts Price Target to $8	MT
24-05-23	B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	MT
24-03-01	HC Wainwright Cuts Price Target on Novavax to $19 From $35, Keeps Buy Rating	MT
24-02-23	B. Riley Trims Novavax's PT to $11 From $12 After Reaching Settlement on Gavi Arbitration Dispute, Keeps Buy Rating	MT
23-12-14	Novavax: green light for updated Covid vaccine in Sweden
23-11-10	B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating	MT
23-08-09	B. Riley Upgrades Novavax to Buy From Neutral After Above-Consensus Q2 Beat, Says Turnaround Progressing; Retains $15 PT	MT
23-05-10	B. Riley Raises Novavax's PT to $15 From $10, Says Q1 Financial Update 'Not As Bad As Feared'; Keeps Neutral Rating	MT
23-03-01	B. Riley Downgrades Novavax to Neutral From Buy, Lowers Price Target to $10 From $29	MT
23-02-17	B. Riley Cuts Novavax's Price Target to $29 From $37, Maintains Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LONZA GROUP AG					+20.9%
	IQVIA HOLDINGS INC.					+2.8%
	REVOLUTION MEDICINES, INC.					+23.88%
	BEONE MEDICINES AG					+19.94%
	CELLTRION, INC.					+50.95%
	MEDPACE HOLDINGS, INC.					-5.99%
	EUROFINS SCIENTIFIC SE					-6.61%
	ASCENDIS PHARMA A/S					+38.36%
	TEMPUS AI, INC.					-19.36%
	Average					+13.88%
	Weighted average by Cap.					+16.97%